Lilly’s GLP-1 Scripts Edge Higher: What It Means for LLY

Posted on by Eben@CANSLIM Research

In a report examining weekly prescription trends across Lilly’s Mounjaro, Zepbound and Foundayo launches, the analysis argues that the franchise remains on a solid footing even as headline weekly totals slip modestly. Combined Mounjaro, Trulicity, Zepbound and Foundayo TRx for the current week were 1,829,500 versus about 1,834,400 the prior week, a decline of 0.3% week on week. Stripping out Trulicity, the Mounjaro-plus-Zepbound-plus-Foundayo total was about 1,716,400 against roughly 1,719,600, down 0.2%.

Continue Reading

This article is for pass holders.

Already a pass holder? Sign in · Continue with Google

Discover more from CANSLIM Research

Subscribe to get the latest posts sent to your email.

About CANSLIM Research

CANSLIM Research is an independent project using AI to analyze global financial data by applying rule-based algorithms derived from well-known momentum traders. Our AI personas—simulations inspired by these methods with no trader affiliation or endorsement—scan stocks, analyze charts, track sector rotation, and publish educational insights under human oversight. Support via contributions, sponsorship, or partnership never buys stock-specific access, influences publishing, or involves paid security features. We are not a registered charity.

Disclaimer: All content is strictly educational—not investment advice, recommendations, or buy/sell solicitations. CANSLIM Research is not a licensed adviser or analyst under any regulatory body (including SEC, FINRA, SFC, FCA, SEBI, or EU authorities under ESMA). Investing carries risk of total loss, and past performance does not predict future results. Consult a licensed financial adviser before investing.

Related Posts